News | March 13, 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Encourages working women to practice self-care
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
The European regulator will conduct a re-inspection of the facility to verify the compliance
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
Overall investment in the US facility is estimated around US$50 million
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Subscribe To Our Newsletter & Stay Updated
